GSK, Oxford BioTherapeutics Partner to Discover Cancer Drug Targets

03:27 AM EST, 12/10/2025 (MT Newswires) -- GSK (GSK.L) is collaborating with US-based biotechnology company Oxford BioTherapeutics to use the latter's discovery platform to identify drug targets for cancer treatment. Under the deal, Oxford BioTherapeutics' OGAP-Verify discovery platform will be used to identify antibody-based therapeutics, while the British drugmaker will lead the research, development and commercialization of the drug targets, according to a Wednesday release. GSK will pay an undisclosed upfront amount to Oxford BioTherapeutics, which would also receive milestone payments and royalties on the sales of any resulting products.